The upsized IPO and AbbVie strategic investment signal strong institutional demand and validate ADARx's siRNA platform. Monitor first-day trading performance and subsequent pipeline updates, particularly around complement-mediated and obesity programs. The AbbVie partnership provides both capital and potential development collaboration.
Price Chart
Executive Summary
ADARx Pharmaceuticals priced its upsized IPO of 26.25M shares at $17.00/share, with gross proceeds of ~$446.3M, plus a concurrent private placement with AbbVie for up to $100M (4.9% stake), bringing total expected proceeds to ~$535.2M. The offering is a major capital event for a late-stage siRNA biotech, providing substantial cash runway and a strategic partnership with AbbVie.
Key Financial Metrics
Key Facts
- IPO of 26,250,000 shares at $17.00/share, expected gross proceeds of ~$446.3M
- Underwriters have 30-day option for additional 3,937,500 shares
- Concurrent private placement with AbbVie for up to $100M at $17.00/share, resulting in ~4.9% ownership
- Total expected gross proceeds of ~$535.2M (excluding underwriter option)
- Shares expected to begin trading on Nasdaq on September 25, 2026 under ticker ADRX
- Offering expected to close on September 28, 2026
- Lead book-running managers: J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank
- AbbVie collaboration and license option agreement for siRNA therapeutics in neuroscience, immunology and oncology
Financial Impact
~$535.2M in total gross proceeds from IPO and concurrent private placement
Risk Factors
- Dilution from 26.25M new shares plus potential 3.94M additional shares from underwriter option
- Execution risk in advancing siRNA pipeline across multiple disease areas
- Reliance on AbbVie collaboration for certain programs; potential for partnership changes
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3368818 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | SC 13G | $17.63 $17.68 | ▲ +0.28% | ▼ −0.05% | $17.81 (+1.02%) |
Oct 5, 2026 21d ago | SC 13D | $18.58 $17.33 | ▼ −6.73% | ▼ −6.49% | $17.81 (−4.14%) |
Oct 2, 2026 24d ago | SC 13D | $19.05 $18.58 | ▼ −2.47% | ▼ −3.02% | $17.81 (−6.51%) |
Oct 1, 2026 25d ago | Press Release | $18.25 $19.05 | ▲ +4.38% | ▲ +3.71% | $17.81 (−2.41%) |
Oct 1, 2026 25d ago | SC 13G | $18.25 $19.05 | ▲ +4.38% | ▲ +3.71% | $17.81 (−2.41%) |
Sep 30, 2026 26d ago | Insider Cluster | $19.54 $18.25 | ▼ −6.60% | ▼ −7.34% | $17.81 (−8.85%) |
Sep 29, 2026 27d ago | Insider Cluster | $19.94 $19.54 | ▼ −2.01% | ▼ −2.18% | $17.81 (−10.68%) |
Sep 25, 2026 4w ago | 424B4 | $20.09 $20.64 | ▲ +2.71% | ▲ +2.90% | $17.81 (−11.35%) |
Sep 25, 2026 4w ago | EFFECT | $19.35 $20.09 | ▲ +3.82% | ▲ +4.57% | $17.81 (−7.96%) |
Sep 24, 2026 4w ago | Press Release | $19.35 $20.09 | ▲ +3.82% | ▲ +4.57% | $17.81 (−7.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers